Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Impilo on the establishment of a continuation fund
Mandate

Vinge advises Impilo on the establishment of a continuation fund

November 15, 2024

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Orphan Drugs, a so-called continuation fund. The continuation fund will have EUR 320m in commitments and will invest in Immedica, in which KKR recently became an owner alongside Impilo.

Impilo is a Nordic investment company specializing in investments within the pharmaceutical, medical technology, healthcare services and other health-related industries. Impilo holds a highly diversified portfolio of healthcare investments and manages approximately EUR 1 billion in capital, from leading Nordic and international investors.

Vinges team consisted of Nils Unckel, Anton Sjökvist and Viktoria Wnuk.

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026